CPC: Churg–Strauss Syndrome with Eosinophilic Myocarditis

A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery

Alana B. Levine, MD
Division of Rheumatology, Hospital for Special Surgery, New York

George Kalliolias, PhD,
Division of Rheumatology, Hospital for Special Surgery, New York

Mark Heaney, MD, PhD
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York

Yoshimi Endo, MD
Assistant Attending Radiologist, Hospital for Special Surgery
Assistant Attending Radiologist, New York Presbyterian Hospital
Assistant Professor of Radiology, Weill Cornell Medical College

Adam Gersten, MD
Department of Pathology, Weill-Cornell Medical College - NewYork Presbyterian Hospital, New York

Jonathan W. Weinsaft, MD
Division of Cardiology, Weill-Cornell Medical College - NewYork Presbyterian Hospital, New York


Robert F. Spiera, MD

Robert F. Spiera, MD

Attending Rheumatologist, Hospital for Special Surgery

Director, Vasculitis and Scleroderma Program, Department of Medicine, Division of Rheumatology, Hospital for Special Surgery

Professor of Clinical Medicine, Weill Cornell Medical College

Attending Physician, New York Presbyterian Hospital, Weill Cornell Medical Center

Anne R. Bass, MD

Anne R. Bass, MD

Associate Attending Physician, Hospital for Special Surgery
Program Director Rheumatology Fellowship Program, Hospital for Special Surgery
Associate Professor of Clinical Medicine, Weill Cornell Medical College

Doruk Erkan, MD, MPH

Doruk Erkan, MD, MPH

Associate Attending Rheumatologist, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
Associate Physician-Scientist, Barbara Volcker Center for Women and Rheumatic Disease

No Abstract Provided

Conclusions
This case exemplifies the diagnostic challenges faced when evaluating patients with hypereosinophila. It also demonstrates the potential severity and fatal consequences of cardiac involvement in CSS. The patient’s complex infectious history complicated the decision to initiate disease-modifying treatment. Randomized clinical trials and studies of investigational treatments are warranted to improve outcomes in CSS patients.

Disclosures
RS receives consulting and research funding from RocheGenentech. All other author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/ licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. Each author certifies that his or her institution has approved the reporting of the case, that all investigations were conducted in conformity with the ethical principles of research, and that informed consent for participating in the study was obtained.

This article appears in HSS Journal: Volume 8, Number 3.
View the full article at springerlink.com.

About the HSS Journal

HSS Journal, an academic peer-reviewed journal published three times a year, February, July and October. The Journal accepts and publishes peer reviewed articles from around the world that contribute to the advancement of the knowledge of musculoskeletal diseases and disorders.

^ Back to Top
Request an Appointment